Arterial pulmonary hypertension in noncardiac intensive care unit

Vascular Health and Risk Management

Volumn 4, Issue 5, 2008, Pages 1043-1060

  Tsapenko, Mykola V ^a   Tsapenko, Arseniy V ^b   Comfere, Thomas B O ^a   Mour, Girish K ^a   Mankad, Sunil V ^a   Gajic, Ognjen ^a  

^a MAYO CLINIC   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Acute cor pulmonale; Acute pulmonary hypertension; Cor pulmonale; Pulmonary hypertension; Right heart failure

Indexed keywords

ADENOSINE; CALCIUM CHANNEL BLOCKING AGENT; DIPYRIDAMOLE; DOBUTAMINE; DOPAMINE; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; ILOPROST; ISOPRENALINE; LEVOSIMENDAN; MILRINONE; NATRIURETIC FACTOR; NESIRITIDE; NIFEDIPINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN E; PROSTAGLANDIN E1; SILDENAFIL; TROPONIN; UNIPROST; VASODILATOR AGENT; VASOPRESSIN; ZAPRINAST;

ACUTE PULMONARY HYPERTENSION; ADULT RESPIRATORY DISTRESS SYNDROME; ARTERY CATHETERIZATION; ARTIFICIAL VENTILATION; BRADYCARDIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRITICALLY ILL PATIENT; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG HALF LIFE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FLUID RESUSCITATION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOTENSION; INTENSIVE CARE; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PULMONARY HYPERTENSION; REVIEW; SEPSIS; TACHYCARDIA; THROMBECTOMY; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE;

ACUTE DISEASE; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; FLUID THERAPY; HUMANS; HYPERTENSION, PULMONARY; INTENSIVE CARE UNITS; RESPIRATION, ARTIFICIAL; RISK FACTORS; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 56849099593     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Adrie C, Holzmann A, Hirani WM, et al. 2000. Effects of intravenous Zaprinast and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome. Anesthesiology, 93:422-30.
2. Albertini M, Ciminaghi B, Mazzola S, et al. 2001. Improvement of respiratory function by bosentan during endotoxic shock in the pig. Prostaglandins Leukot Essent Fatty Acids, 65:103-8.
3. Arafa OE, Geiran OR, Andersen K, et al. 2000. Intraaortic balloon pumping for predominantly right ventricular failure after heart transplantation. Ann Thorac Surg, 70:1587-93.
4. Atz AM, Wessel DL. 1999. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology, 91:307-10.
5. Aubert S, Leprince P, Bonnet N, et al. 2006. Limited mechanical circulatory support following orthotopic heart transplantation. Interact Cardiovasc Thorac Surg, 5:88-9.
6. Aubin MC, Laurendeau S, Mommerot A, et al. 2008. Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass. J Cardiovasc Pharmacol, 51:11-7.
7. Badesch DB, Abman SH, Simonneau G, et al. 2007. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest, 131:1917-28.
8. Balanos GM, Talbot NP, Dorrington KL, et al. 2003. Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography. J Appl Physiol, 941543-51.
9. Barst RJ, McGoon M, Torbicki A, et al. 2004. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 43(12 Suppl S)40S-47S.
10. Barton P, Garcia J, Kouatli A, et al. 1996. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest, 109:1302-12.
11. Berisha S, Kastrati A, Goda A, et al. 1990. Optimal value of filling pressure in the right side of the heart in acute right ventricular infarction. Br Heart J, 63:98-102.
12. Bernstein AD, Parsonnet V. 2000. Bedside estimation of risk as an aid for decision-making in cardiac surgery. Ann Thorac Surg, 69:823-8.
13. Bhorade S, Christenson J, O'Connor M, et al. 1999. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med, 159:571-9.
14. Blaise G, Langleben D, Hubert B. 2003. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology, 99:1415-32.
15. Bossone E, Bodini BD, Mazza A, et al. 2005. Pulmonary arterial hypertension: the key role of echocardiography. Chest, 127:1836-43.
16. Bradford KK, Deb B, Pearl RG. 2000. Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbit. J Cardiovasc Pharmacol, 36:146-51.
17. Brimioulle S, Vachiery JL, Brichant JF, et al. 1997. Sympathetic modulation of hypoxic pulmonary vasoconstriction in intact dogs. Cardiovasc Res, 34:384-92.
18. Buller HR, Agnelli G, Hull RD, et al. 2004. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126(3 Suppl):401S-28S.
19. Cargill RI, Lipworth BJ. 1995. Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. Br J Clin Pharmacol, 40:585-90.
20. Cargill RI, Lipworth BJ. 1996. Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects. Chest, 110:1220-5.
21. Caruso LJ, Layon AJ, Gabrielli A. 2002. What is the best way to measure cardiac output? Who cares, anyway? Chest, 122:771-4.
22. Chemla D, Castelain V, Herve P, et al. 2002. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J, 20:1314-31.
23. Chen EP, Bittner HB, Davis RD, Jr., et al. 1997. Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. Ann Thorac Surg, 63:814-21.
24. Chin KM, Kim NH, Rubin RJ. 2005. The right ventricle in pulmonary hypertension. Coron Artery Dis, 16:13-8.
25. Christenson J, Lavoie A, O'Connor M, et al. 2000. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med, 161:1443-9.
26. Cockrill BA, Kacmarek RM, Fifer MA, et al. 2001. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest, 119:128-36.
27. Deb B, Bradford K, Pearl RG. 2000. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit Care Med, 28:795-9.
28. Della Rocca G, Coccia C. 2005. Nitric oxide in thoracic surgery. Minerva Anestesiol, 71:313-18.
29. Domenighetti G, Stricker H, Waldispuehl B. 2001. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit Care Med, 29:57-62.
30. Engelke C, Rummeny E, Marten K. 2006. [Acute pulmonary embolism: prediction of cor pulmonale and short-term patient survival from assessment of cardiac dimensions in routine multidetector-row CT]. Rofo, 178:999-1006.
31. Evora PR, Pearson PJ, Schaff HV. 1993. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest, 103:1241-5.
32. Felker GM, Benza RL, Chandler AB, et al. 2003. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol, 41:997-1003.
33. Fierobe L, Brunet F, Dhainaut JF, et al. 1995. Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome. Am J Respir Crit Care Med, 151:1414-9.
34. Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol, 44:340-8.
35. Foubert L, De Wolf D, Reyntjens K, et al. 2003. Intermittent nitric oxide combined with intravenous dipyridamole in a piglet model of acute pulmonary hypertension. Anesth Analg, 97:1497-500.
36. Fullerton DA, Jaggers J, Jones SD, et al. 1996. Adenosine for refractory pulmonary hypertension. Ann Thorac Surg, 62:874-7.
37. Fung E, Fiscus RR, Yim AP, et al. 2005. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest, 128:3065-73.
38. Galie N, Torbicki A, Barst R, et al. 2004. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J, 25:2243-78.
39. Gelvez J, Fakioglu H, Olarte JL, et al. 2004. Effect of aerosolized milrinone during drug-induced pulmonary hypertension in lambs. Pharmacol Res, 50:87-91.
40. George I, Xydas S, Topkara VK, et al. 2006. Clinical indication for use and outcomes after inhaled nitric oxide therapy. Ann Thorac Surg, 82:2161-9.
41. Ghofrani HA, Rose F, Schermuly RT, et al. 2002. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med, 136:515-22.
42. Ghofrani HA, Wiedemann R, Rose F, et al. 2003. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol, 42:158-64.
43. Gomberg-Maitland M, Olschewski H. 2008. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J, 31:891-901.
44. Hache M, Denault AY, Belisle S, et al. 2001. Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. Can J Anaesth, 48:924-9.
45. Hashiba E, Hirota K, Yoshioka H, et al. 2000. Milrinone attenuates serotonin-induced pulmonary hypertension and bronchoconstriction in dogs. Anesth Analg, 90:790-4.
46. Hentschel T, Yin N, Riad A, et al. 2007. Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology, 106:124-31.
47. Hickey PR, Retzack SM. 1993. Acute right ventricular failure after pulmonary hypertensive responses to airway instrumentation: effect of fentanyl dose. Anesthesiology, 78:372-6.
48. Hirsch LJ, Rooney MW, Wat SS, et al. 1991. Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolism. Chest, 100:796-801.
49. Hoeper MM, Galie N, Murali S, et al. 2002. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med, 165:341-4.
50. Hohn L, Schweizer A, Morel DR, et al. 1999. Circulatory failure after anesthesia induction in a patient with severe primary pulmonary hypertension. Anesthesiology, 91:1943-5.
51. Holloway EL, Polumbo RA, Harrison DC. 1975. Acute circulatory effects of dopamine in patients with pulmonary hypertension. Br Heart J, 37:482-5.
52. Humbert M, Morrell NW, Archer SL, et al. 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol, 43(12 Suppl S):13S-24S.
53. Ivy DD, Kinsella JP, Ziegler JW, et al. 1998. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg, 115:875-92.
54. Jacobs AK, Leopold JA, Bates E, et al. 2003. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol, 41:1273-9.
55. Jardin F, Delorme G, Hardy A, et al. 1990. Reevaluation of hemodynamic consequences of positive pressure ventilation: emphasis on cyclic right ventricular afterloading by mechanical lung inflation. Anesthesiology, 72:966-70.
56. Jardin F, Vieillard-Baron A. 2007. Is there asafe plateau pressure in ARDS? The right heart only knows. Intensive Care Med, 33:444-7.
57. Jeon Y, Ryu JH, Lim YJ, et al. 2006. Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. Eur J Cardiothorac Surg, 29:952-6.
58. Johnson RF, Loyd JE, Mullican AL, et al. 2007. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. J Heart Lung Transplant, 26:363-9.
59. Kaisers U, Busch T, Deja M, et al. 2003. Selective pulmonary vasodilation in acute respiratory distress syndrome. Crit Care Med, 31(4 Suppl): S337-42.
60. Karski JM. 2003. Transesophageal echocardiography in the intensive care unit. Semin Cardiothorac Vasc Anesth, 10:162-6.
61. Kasper W, Konstantinides S, Geibel A, et al. 1997. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol, 30:1165-71.
62. Kerbaul F, Gariboldi V, Giorgi R, et al. 2007. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med, 35:1948-54.
63. Kerbaul F, Rondelet B, Motte S, et al. 2004. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med, 32:1035-40.
64. Klein A, Zils U, Bopp C, et al. 2007. Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats. J Surg Res, 138:224-30.
65. Klepetko W, Mayer E, Sandoval J, et al. 2004. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol, 43(12 Suppl S):73S-80S.
66. Klinger JR, Thaker S, Houtchens J, et al. 2006. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest, 129:417-25.
67. Krupicka J, Janota T, Kasalova Z, et al. 2008. Natriuretic peptides-physiology, pathophysiology and clinical use in heart failure. Physiol Res, Apr 1.
68. Kwak YL, Lee CS, Park YH, et al. 2002. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension. Anaesthesia, 57:9-14.
69. La Vecchia L, Ottani F, Favero L, et al. 2004. Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism. Heart, 90:633-7.
70. Lamarche Y, Malo O, Thorin E, et al. 2005. Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg, 130:83-92.
71. Lambermont B, Ghuysen A, Kolh P, et al. 1999. Analysis of endotoxin effects on the intact pulmonary circulation. Cardiovasc Res, 41:275-81.
72. Lambermont B, Kolh P, Detry O, et al. 2003. Effects of endotoxic shock on right ventricular systolic function and mechanical efficiency. Cardiovasc Res, 59:412-18.
73. Leather HA, Segers P, Berends N, et al. 2002. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med, 30:2548-52.
74. Lee JH, Oh YJ, Shim YH, et al. 2006. The effect of milrinone on the right ventricular function in patients with reduced right ventricular function undergoing off-pump coronary artery bypass graft surgery. J Korean Med Sci, 21:854-8.
75. Leeman M. 1999. Pulmonary hypertension in acute respiratory distress syndrome. Monaldi Arch Chest Dis, 54:146-9.
76. Lepore JJ, Dec GW, Zapol WM, et al. 2005. Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients. J Heart Lung Transplant, 24:1950-6.
77. Lepore JJ, Maroo A, Bigatello LM, et al. 2005. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest, 127:1647-53.
78. Leuchte HH, Holzapfel M, Baumgartner RA, et al. 2004. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol, 43:764-70.
79. Levy JH, Bailey JM, Deeb GM. 2002. Intravenous milrinone in cardiac surgery. Ann Thorac Surg, 73:325-30.
80. Lobato EB, Beaver T, Muehlschlegel J, et al. 2006. Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. Br J Anaesth, 96:317-22.
81. Matot I, Gozal Y. 2004. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest, 125:644-51.
82. McConnell MV, Solomon SD, Rayan ME, et al. 1996. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol, 78:469-73.
83. McIntyre RC, Jr., Moore FA, Moore EE, et al. 1995. Inhaled nitric oxide variably improves oxygenation and pulmonary hypertension in patients with acute respiratory distress syndrome. J Trauma, 39:418-25.
84. McLaughlin VV, Genthner DE, Panella MM, et al. 1998. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med, 338:273-7.
85. McLaughlin VV, Shillington A, Rich S. 2002. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation, 106:1477-82.
86. McNeil K, Dunning J, Morrell NW. 2003. The pulmonary physician in critical care. 13: the pulmonary circulation and right ventricular failure in the ITU. Thorax, 58:157-62.
87. McQuillan BM, Picard MH, Leavitt M, et al. 2001. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation, 104:2797-802.
88. Meadow WL, Rudinsky BF, Strates E. 1986. Selective elevation of systemic blood pressure by epinephrine during sepsis-induced pulmonary hypertension in piglets. Pediatr Res, 20:872-5.
89. Mehra MR, Ventura HO, Kapoor C, et al. 1997. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol, 80:61-4.
90. Mehta NJ, Jani K, Khan IA. 2003. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J, 145:821-5.
91. Michaels AD, Chatterjee K, De Marco T. 2005. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Card Fail, 11:425-31.
92. Michelakis E, Tymchak W, Lien D, et al. 2002. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation, 105:2398-403.
93. Mikhail GW, Prasad SK, Li W, et al. 2004. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J, 25:431-6.
94. Milot J, Perron J, Lacasse Y, et al. 2001. Incidence and predictors of ARDS after cardiac surgery. Chest, 119:884-8.
95. Miranda DR, Klompe L, Cademartiri F, et al. 2006. The effect of open lung ventilation on right ventricular and left ventricular function in lung-lavaged pigs. Crit Care, 10:R86.
96. Missant C, Rex S, Segers P, et al. 2007. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med, 35:707-15.
97. Moloney ED, Evans TW. 2003. Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome. Eur Respir J, 21:720-7.
98. Moreira MM, Terzi RG, Vieira RW, et al. 2007. Pre- and post-pulmonary thromboendarterectomies captiographic variables. Rev Bras Cir Cardiovasc, 22:509-12.
99. Morelli A, Teboul JL, Maggiore SM, et al. 2006. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med, 34:2287-93.
100. Motti A, Tissot C, Rimensberger PC, et al. 2006. Intravenous adenosine for refractory pulmonary hypertension in a low-weight premature newborn: a potential new drug for rescue therapy. Pediatr Crit Care Med, 7:380-2.
101. Nagaya N, Nishikimi T, Uematsu M, et al. 2000. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation, 102:865-70.
102. Namachivayam P, Theilen U, Butt WW, et al. 2006. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med, 174:1042-7.
103. Nath J, Foster E, Heidenreich PA. 2004. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol, 43:405-9.
104. Nenci GG, Berrettini M, Todisco T, et al. 1988. Effects of dipyridamole on the hypoxemic pulmonary hypertension of patients with chronic obstructive pulmonary disease. Respiration, 53:13-9.
105. Ng C, Franklin O, Vaidya M, et al. 2004. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med, 5:10-13.
106. Ng J, Finney SJ, Shulman R, et al. 2005. Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil? Br J Anaesth, 94:774-7.
107. Ocal A, Kiris I, Erdinc M, et al. 2005. Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension. Tohoku J Exp Med, 207:51-8.
108. Ozdogan ME, Erer D, Iriz E, et al. 2008. Right-to-left shunt through a patent foramen ovale left open in the management of acute right heart failure after heart transplantation. J Heart Lung Transplant, 27:135-7.
109. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. 1991. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet, 338:1173-4.
110. Prielipp RC, McLean R, Rosenthal MH, et al. 1991. Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. Crit Care Med, 19:60-7.
111. Raymond RJ, Hinderliter AL, Willis PW, et al. 2002. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol, 39:1214-19.
112. Reis Miranda D, Gommers D, Struijs A, et al. 2004. The open lung concept: effects on right ventricular afterload after cardiac surgery. Br J Anaesth, 93:327-32.
113. Reynolds HR, Hochman JS. 2008. Cardiogenic shock: current concepts and improving outcomes. Circulation, 117:686-97.
114. Roberts DH, Lepore JJ, Maroo A, et al. 2001. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest, 120:1547-55.
115. Sandoval J, Rothman A, Pulido T. 2001. Atrial septostomy for pulmonary hypertension. Clin Chest Med, 22:547-60.
116. Santos C, Ferrer M, Roca J, et al. 2000. Pulmonary gas exchange response to oxygen breathing in acute lung injury. Am J Respir Crit Care Med, 161:26-31.
117. Schmitt JM, Vieillard-Baron A, Augarde R, et al. 2001. Positive end-expiratory pressure titration in acute respiratory distress syndrome patients: impact on right ventricular outflow impedance evaluated by pulmonary artery Doppler flow velocity measurements. Crit Care Med, 29:1154-8.
118. Schneider C, Schwemmer U, Kredel M, et al. 2007. Handheld vs conventional transesophageal echocardiography in non-cardiac surgical intensive care unit patients. Ultraschall Med, Aug 3.
119. Selimovic N, Rundqvist B, Bergh CH, et al. 2007. Assessment of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension. J Heart Lung Transplant, 26:927-34.
120. Sibbald WJ, Paterson NA, Holliday RL, et al. 1978. Pulmonary hypertension in sepsis: measurement by the pulmonary arterial diastolic-pulmonary wedge pressure gradient and the influence of passive and active factors. Chest, 73:583-91.
121. Solina A, Papp D, Ginsberg S, et al. 2000. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth, 14:12-17.
122. Stiebellehner L, Petkov V, Vonbank K, et al. 2003. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest, 123:1293-5.
123. Stobierska-Dzierzek B, Awad H, Michler RE. 2001. The evolving management of acute right-sided heart failure in cardiac transplant recipients, J Am Coll Cardiol, 38:923-31.
124. Stocker CF, Shekerdemian LS, Norgaard MA, et al. 2007. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass. Crit Care Med, 35:252-9.
125. Subramaniam K, Yared JP. 2007. Management of pulmonary hypertension in the operating room. Semin Cardiothorac Vasc Anesth, 11:119-36.
126. Sulica R, Dinh HV, Dunsky K, et al. 2005. The acute hemodynamic effect of IV nitroglycerin and dipyridamole in patients with pulmonary arterial hypertension: comparison with IV epoprostenol. Congest Heart Fail, 11:139-44; quiz 145-6.
127. Tayama E, Ueda T, Shojima T, et al. 2007. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg, 6:715-19.
128. Taylor RW, Zimmerman JL, Dellinger RP, et al. 2004. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA, 291:1603-9.
129. Theodoraki K, Rellia P, Thanopoulos A, et al. 2002. Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth, 49:963-7.
130. Tisdale JE, Patel RV, Webb CR, et al. 1995. Proarrhythmic effects of intravenous vasopressors. Ann Pharmacother, 29:269-81.
131. Trachte AL, Lobato EB, Urdaneta F, et al. 2005. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg, 79:194-7.
132. Trempy GA, Nyhan DP, Murray PA. 1994. Pulmonary vasoregulation by arginine vasopressin in conscious, halothane-anesthetized, and pentobarbital-anesthetized dogs with increased vasomotor tone. Anesthesiology, 81:632-40.
133. Tritapepe L, Voci P, Cogliati AA, et al. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Crit Care Med, 27:2180-3.
134. Troncy E, Francoeur M, Blaise G. Inhaled nitric oxide: clinical applications, indications, and toxicology. Can J Anaesth, 44:973-88.
135. Via G, Braschi A. 2004. Pathophysiology of severe pulmonary hypertension in the critically ill patient. Minerva Anestesiol, 70:233-7.
136. Vieillard-Baron A, Loubieres Y, Schmitt JM, et al. 1999. Cyclic changes in right ventricular output impedance during mechanical ventilation. J Appl Physiol, 87:1644-50.
137. Vieillard-Baron A, Page B, Augarde R, et al. 2001a. Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rate. Intensive Care Med, 27:1481-6.
138. Vieillard-Baron A, Prin S, Chergui K, et al. 2002. Echo-Doppler demonstration of acute cor pulmonale at the bedside in the medical intensive care unit. Am J Respir Crit Care Med, 166:1310-19.
139. Vieillard-Baron A, Schmitt JM, Augarde R, et al. 2001b. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis. Crit Care Med, 29:1551-5.
140. Vizza CD, Rocca GD, Roma AD, et al, 2001. Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care, 5:355-61.
141. Wallace AW, Tunin CM, Shoukas AA. 1989. Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol, 257(4 Pt 2):H1228-34.
142. Wort SJ, Evans TW. 1999. The role of the endothelium in modulating vascular control in sepsis and related conditions. Br Med Bull, 55:30-48.
143. Wynne R, Botti M. 2004. Postoperative pulmonary dysfunction in adults after cardiac surgery with cardiopulmonary bypass: clinical significance and implications for practice. Am J Crit Care, 13:384-93.
144. Yancy CW, Krum H, Massie BM, et al. 2007. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. Am Heart J, 153:478-84.
145. Yoshida M, Inoue I, Kawagoe T, et al. 2006. Novel percutaneous catheter thrombectomy in acute massive pulmonary embolism: rotational bidirectional thrombectomy (ROBOT). Catheter Cardiovasc Interv, 68:112-17.
146. Yurtseven N, Karaca P, Kaplan M, et al. 2003. Effect of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery. Anesthesiology, 99:855-8.
147. Zamanian RT, Haddad F, Doyle RL, et al. 2007. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med, 35:2037-50.
148. Ziegler JW, Ivy DD, Wiggins JW, et al. 1998. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med, 158(5 Pt 1):1388-95.
149. Zwissler B, Welte M, Messmer K. 1995. Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction. J Cardiothorac Vasc Anesth, 9:283-9.